The Latest Cardiac and Vascular News
BOSTON, May 16, 2024 /PRNewswire/ — Heart Rhythm Society (HRS) Conference — Circle Cardiovascular Imaging Inc. and inHEART Inc. announced today a global distribution agreement enabling Circle to promote and market inHEART’s advanced, AI-enabled digital twin of the heart through Circle’s…
Promising results from the EMAGINE randomized trial suggest that treatment with BRAIN.Q’s AI-powered low electromagnetic field stimulation, aimed at enhancing the brain’s ability to relearn processes lost after a stroke, may help patients regain ‘freedom from disability’ with greater…
With these latest studies, the firmly established European market leader in stroke AI imaging adds to its growing body of evidence. The latest research reflects the company’s extensive academic collaborations and its growing Life Science partnerships. OXFORD, England and CHICAGO, May 16,…
Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial
COPENHAGEN, Denmark, May 16, 2024 /PRNewswire/ — Globally, cardiovascular diseases due to atherosclerosis – the build-up of plaque in arteries – are the leading cause of death. A new Danish-Spanish research collaboration aims to develop methods to detect atherosclerosis at earlier ages…
Real-time Vessel Measurement Informs Physician Treatment Decisions SAN DIEGO, May 15, 2024 /PRNewswire/ — Provisio Medical, Inc., pioneers of Sonic Lumen Tomography™ (SLT) technology to provide real-time blood vessel measurements during vascular interventions, today announced the…
HAYWARD, Calif.–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology (“Pulse”), today announced enhancements to its executive leadership team to support its next pivotal phase of growth. “Together with Burke’s expertise and Kevin leading as Chief Commercial Officer, Pulse Biosciences is […]
PARIS–(BUSINESS WIRE)–Regulatory News: “ACTISAVE Clinical Trial: Efficacy and Safety of Glenzocimab on Top of Thrombolysis with or without Mechanical Thrombectomy.” Post this ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT) (Paris:ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, including stroke, announces the presentation, […]
SAN DIEGO–(BUSINESS WIRE)–Vektor Medical, a pioneer in non-invasive, AI-based arrhythmia analysis technology, today unveiled a comprehensive schedule of educational content and sessions featuring the use of vMap® at this year’s Heart Rhythm 2024 conference in Boston, May 16-19. vMap rapidly provides actionable arrhythmia localization insights for physicians. The research and presentations at HRS […]
LONDON–(BUSINESS WIRE)–BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces that AstraZeneca has added a novel target for Heart Failure to its discovery portfolio through its collaboration with BenevolentAI. Novel target for Heart Failure was discovered using BenevolentAI’s AI-drug […]
